Edge
StocktwitsEarnings

Official STOCKTWITS Representative

$LGND Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $2.42 up 868.00% YoY
• Reported revenue of $63.69M up 33.73% YoY
• Ligand Pharmaceuticals is reaffirming its 2026 full-year revenue guidance and is raising the low end of its adjusted earnings per diluted share guidance range to approximately $9.00 to $9.50.Price since post